Optimized Drug Treatment for Takotsubo Broken Heart Syndrome in Adults A Large Multinational Randomized Trial
Led by Vastra Gotaland Region · Updated on 2024-12-02
1000
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating optimized pharmacologic treatments for patients with Takotsubo Syndrome, a condition often referred to as broken heart syndrome. This large randomized registry clinical trial aims to include 1000 participants registered in SWEDEHEART to better document effective treatments, as current data from large patient groups are lacking. The trial is a Phase 4 study sponsored by Vastra Gotaland Region and is designed as an open-label, multinational, multicenter trial.
Participants are randomly assigned to different treatment groups. One group receives an adenosine infusion for 3 hours followed by oral dipyridamole twice daily until left ventricular function normalizes or up to about one month. Another group receives usual care per European Society of Cardiology recommendations. A separate randomization compares oral apixaban twice daily until normalization of heart function or about one month versus no anticoagulant therapy. The study monitors heart function with echocardiographic assessments at 48-96 hours and possibly later.
During the study, participants undergo regular heart ultrasounds to assess wall motion and ejection fraction, along with monitoring for events such as death, cardiac arrest, heart failure, thromboembolic events, and bleeding. The trial collects data up to 30 days after treatment begins. Researchers also track heart rhythm problems and use standardized scoring to evaluate heart muscle movement. Safety and treatment outcomes are closely observed throughout the study period, which lasts until December 2028.
CONDITIONS
Brief Title
BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
Research Team
E
Elmir Omerovic, MD PhD
B
Björn Redfors, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinical diagnosis of Takotsubo Syndrome with ejection fraction of 50% or higher at baseline
Written informed consent obtained
You will not qualify if you...
Previous participation in this trial
Life expectancy less than one month due to other conditions
Previously diagnosed left ventricular ejection fraction below 50%
Known cardiomyopathy except previous Takotsubo Syndrome
Significant valve disease or stenosis
Heart transplant or left ventricular assist device recipient
Hemoglobin less than 10 g/dL within the last 3 months
Systolic blood pressure below 80 mm Hg at screening
Severe kidney disease or current dialysis
Pregnancy or of childbearing potential without contraception or sterilization
Severe or terminal comorbidity affecting trial adherence
For adenosine/dipyridamole group: contraindications including certain heart blocks, unstable angina, severe asthma or COPD, ongoing dipyridamole treatment, or declined participation
For apixaban group: contraindications for anticoagulant treatment, current need for anticoagulants or dual antiplatelet therapy, or declined participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 30+7 days or until normalization of heart function
Participants receive pharmacological treatments including adenosine infusion followed by dipyridamole, or apixaban oral tablets, or usual care as per clinical guidelines until heart function normalizes or for approximately 30 days.
Daily medication dosing with echocardiographic assessments at 48-96 hours and possibly later
Follow-up
Duration - Up to 30 days
Participants are monitored for clinical outcomes such as heart function, thromboembolic events, and other complications up to 30 days after treatment begins.
Assessments at 48-96 hours and up to day 30
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Optimized Drug Treatment for Takotsubo Broken Heart Syndrome in Adults A Large Multinational Randomized Trial
Study on Causes and Outcomes of Stroke-Heart Syndrome
Using Imaging and Blood Analysis in Stroke Patients
Polish Registry Tracking Patients With Takotsubo Syndrome
Study on Air Pollution Exposure and Takotsubo Syndrome Risk and Outcomes
International Registry Collecting Data on Patients with Takotsubo Syndrome from Germany, Italy, and Spain
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome.